ArticleJournal of veterinary internal medicine2020
Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
Article in Journal of veterinary internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- New variants in ACE gene region in 10 Cavalier King Charles Spaniel dogs with mild and severe myxomatous mitral valve disease - preliminary study.Veterinary and animal science · 2026Article
- Pre-anaesthetic risk assessment and management of dogs with myxomatous mitral valve disease: a spectrum of care narrative review.The Journal of small animal practice · 2026Review
- Prognostic characteristics of preoperative serum total bilirubin concentration in myxomatous mitral valve disease in dogs undergoing mitral valve repair.Journal of veterinary internal medicine · 2026Article
- Prevalence of rs850683722 Variant and Its Influence on the Course of Myxomatous Mitral Valve Disease in 105 Cavalier King Charles Spaniel Dogs in the Polish Population.Animals : an open access journal from MDPI · 2026Article
- Prognostic value of plasma cortisol concentration in dogs with congestive heart failure.Journal of veterinary internal medicine · 2026Article
- Outcomes of mitral valve repair in dogs with myxomatous mitral valve disease and preoperative atrial fibrillation.Journal of veterinary internal medicine · 2026Article
- Pilot study on the effects of dapagliflozin on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve disease.Veterinary and animal science · 2025Article
- Genetic Basis of Myxomatous Mitral Valve Disease in Cavalier King Charles Spaniel Dogs-A Review.Veterinary sciences · 2025Review
- Impact of administering cardiac medication to small-breed dogs with preclinical myxomatous mitral valve disease on survival after congestive heart failure onset.The veterinary quarterly · 2025Article
- Pimobendan alleviates myocyte apoptosis and fibrosis associated with mitral regurgitation by targeting endoplasmic reticulum stress.Animal models and experimental medicine · 2025Article
- Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the "right drug" and the "right dose" for dogs.The Journal of veterinary medical science · 2025Review
- Management of two dogs with post-operative new-onset persistent atrial fibrillation following mitral valve repair.Veterinary medicine and science · 2025Article
- Alteration of clinical parameters before mortality and prognostic outcomes of pulmonary hypertension in dogs with myxomatous mitral valve disease.Open veterinary journal · 2024Article
- Self-Reported Utilization of International (ACVIM Consensus) Guidelines and the Latest Clinical Trial Results on the Treatment of Dogs with Various Stages of Myxomatous Mitral Valve Degeneration: A Survey among Veterinary Practitioners.Animals : an open access journal from MDPI · 2024Article
- Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.BMC veterinary research · 2023Article
- Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation.BMC veterinary research · 2023Article
- Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs.International journal of molecular sciences · 2023Article
- Retrospective evaluation of risk factors for development of kidney injury after parenteral furosemide treatment of left-sided congestive heart failure in dogs.Journal of veterinary internal medicine · 2022Article
- Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.Animals : an open access journal from MDPI · 2022Review
- Prevalence of an angiotensin-converting enzyme gene variant in dogs.Canine medicine and genetics · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundTriple therapy (TT) consisting of furosemide, pimobendan, and an angiotensin-converting enzyme inhibitor (ACEI) frequently is recommended for the treatment of congestive heart failure (CHF) attributable to myxomatous mitral valve disease (MMVD). However, the effect of adding an ACEI to the combination of pimobendan and furosemide (dual therapy [DT]) so far has not been evaluated prospectively. HYPOTHESIS: Triple therapy will extend survival time compared to DT in dogs with CHF secondary to MMVD. ANIMALS: Client-owned dogs presented with the first episode of CHF caused by MMVD.
methodsProspective, single-blinded, randomized multicenter study. One-hundred and fifty-eight dogs were recruited and prospectively randomized to receive either DT (furosemide and pimobendan) or TT (furosemide, pimobendan, and ramipril). The primary endpoint was a composite of cardiac death, euthanasia for heart failure, or treatment failure.
resultsSeventy-seven dogs were randomized to receive DT and 79 to receive TT. Two dogs were excluded from analysis. The primary endpoint was reached by 136 dogs (87%; 66 dogs, DT; 70 dogs, TT). Median time to reach the primary endpoint for all dogs in the study was 214 days (95% confidence interval [CI], 168-259 days). Median time to reach the primary endpoint was not significantly different between the DT group (227 days; interquartile range [IQR], 103-636 days) compared with TT group (186 days; IQR, 72-453 days; P = .42). CONCLUSIONS AND CLINICAL IMPORTANCE: Addition of the ACEI ramipril to pimobendan and furosemide did not have any beneficial effect on survival time in dogs with CHF secondary to MMVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.